Lataa...
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
BACKGROUND: Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. DESIGN AND METHODS: Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3(rd) year, allowing cardiac iron removal to be analyzed over three y...
Tallennettuna:
Päätekijät: | , , , , , , , , , , , , , , , |
---|---|
Aineistotyyppi: | Artigo |
Kieli: | Inglês |
Julkaistu: |
Ferrata Storti Foundation
2012
|
Aiheet: | |
Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3366648/ https://ncbi.nlm.nih.gov/pubmed/22271905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.049957 |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|